1. Introduction: A Claim That Was Tested and Failed
High-dose vitamin C (ascorbic acid) has been proposed as a cancer treatment since the 1970s, when Linus Pauling and Ewan Cameron reported that oral ascorbate prolonged survival in patients with advanced cancer. That claim was tested in randomized trials and was not confirmed. Interest revived decades later with the observation that intravenous (not oral) high-dose vitamin C achieves far higher blood concentrations and may, in theory, have anticancer effects. The modern question is whether those pharmacological insights translate into clinical benefit. At present, high-dose intravenous vitamin C remains investigational and unproven as a cancer treatment.
2. The Pharmacological Rationale
Ascorbate is water-soluble, actively absorbed, and tightly regulated by the body; oral intake beyond a modest threshold produces little further increase in plasma concentration because absorption and renal reabsorption are saturable. Intravenous administration bypasses this control and can produce plasma concentrations in the millimolar range — roughly a hundred-fold higher than achievable orally. At these concentrations, ascorbate can act as a pro-oxidant, generating hydrogen peroxide in the extracellular fluid. Some cancer cells, which often express high levels of glucose transporters such as GLUT1, accumulate more ascorbate and may be more susceptible to this oxidative stress because they have lower antioxidant capacity. This differential is the basis for the hypothesis that high-dose intravenous vitamin C could selectively harm tumor cells. These are plausible mechanisms demonstrated in laboratory and animal models; plausibility is not proof of clinical benefit.
3. What the Trials Showed
3.1. The Original Claim and Its Refutation
Cameron and Pauling’s 1976 report was a non-randomized comparison, a design vulnerable to bias. Two randomized, placebo-controlled trials at the Mayo Clinic tested high-dose oral vitamin C in advanced cancer and found no benefit in survival or tumor response. The discrepancy between the original claim and the randomized results is the classic example of why controlled trials are necessary. Note that these trials tested oral vitamin C, which does not achieve the millimolar plasma concentrations that motivate current intravenous research.
3.2. Modern Intravenous Trials
Contemporary phase I and phase II trials of high-dose intravenous vitamin C, usually given with standard chemotherapy or radiotherapy, have primarily assessed safety, tolerability, and quality of life rather than survival. Some studies report acceptable tolerability and possible reductions in treatment-related toxicity; others report no clear benefit. Reliable evidence that intravenous vitamin C improves cancer outcomes (survival, response, or recurrence) is lacking. It should therefore be described as an investigational adjunct, not an established therapy.
4. Safety: Not Without Risk at High Doses
High-dose intravenous vitamin C is not risk-free. Recognized concerns include:
- Hemolysis in glucose-6-phosphate dehydrogenase (G6PD) deficiency, which is a reason for screening before administration.
- Oxalate nephropathy and kidney injury from oxalate load, particularly in patients with renal impairment.
- Iron overload toxicity in patients with hemochromatosis or transfusional iron loading, since ascorbate increases iron absorption and can potentiate oxidative injury.
- Electrolyte and fluid issues (for example, hypernatremia from the sodium ascorbate preparation) and interactions with laboratory tests (falsely elevated glucose readings).
Because it may interfere with chemotherapy or radiotherapy — either favorably or unfavorably — administration during active treatment should be supervised and studied rather than assumed.
5. Early Research and Emerging Approaches
- Ongoing randomized trials are testing intravenous vitamin C as an adjunct in specific cancers (for example, with chemotherapy in pancreatic, lung, and brain tumors). These will determine whether any subgroup benefits.
- Research into the molecular determinants of sensitivity (transporter expression, redox biology) may eventually allow patient selection.
6. Unresolved Questions and Speculative Directions
- Whether high-dose intravenous vitamin C provides any meaningful survival or quality-of-life benefit in any cancer type is unproven. [Marked for verification.]
- Whether it can be combined safely and beneficially with specific chemotherapies remains an open and actively studied question.
7. Conclusion
High-dose intravenous vitamin C rests on an interesting pharmacological rationale — millimolar plasma concentrations and pro-oxidant effects — but lacks evidence of clinical benefit in cancer. The original oral-vitamin claim was refuted by randomized trials, and modern intravenous trials have not demonstrated improved outcomes. It carries real, if uncommon, risks such as hemolysis in G6PD deficiency and oxalate nephropathy. It should be regarded as an investigational adjunct to be used only within supervised trials, never as a replacement for proven cancer treatment.
Sources and Key Research Centers
- National Cancer Institute — PDQ summary on high-dose vitamin C.
- NCI Office of Cancer Complementary and Alternative Medicine — reviews of vitamin C in cancer.
- Original claim
- Cameron E, Pauling L. «Supplemental ascorbate in the supportive treatment of cancer: prolongation of survival times in terminal human cancer.» Proceedings of the National Academy of Sciences, 1976; 73(10): 3685–3689. [Verify.]
- Randomized refutation (oral vitamin C)
- Creagan ET, Moertel CG, O’Fallon JR, et al. «Failure of high-dose vitamin C (ascorbic acid) therapy to benefit patients with advanced cancer: a controlled trial.» New England Journal of Medicine, 1979; 301(13): 687–690. [Verify.]
- Moertel CG, Fleming TR, Creagan ET, et al. «High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy: a randomized double-blind comparison.» New England Journal of Medicine, 1985; 312(3): 137–141. [Verify.]
- Pharmacokinetics of ascorbate
- Levine M, Conry-Cantilena C, Wang Y, et al. «Vitamin C pharmacokinetics in healthy volunteers: evidence for a recommended dietary allowance.» Proceedings of the National Academy of Sciences, 1996; 93(8): 3704–3709. [Verify.]
- ClinicalTrials.gov — ongoing trials of intravenous vitamin C with chemotherapy (search terms: intravenous vitamin C cancer, ascorbate chemotherapy).
Note: citation identifiers are provided where available; readers should confirm bibliographic details against the publisher’s record. This article is an editorial scientific overview and is not a medical recommendation.